ISCO Stock Overview
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
International Stem Cell Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.10 |
52 Week High | US$0.22 |
52 Week Low | US$0.046 |
Beta | 0.47 |
1 Month Change | 26.73% |
3 Month Change | 60.89% |
1 Year Change | -37.79% |
3 Year Change | -85.94% |
5 Year Change | -91.79% |
Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
ISCO | US Biotechs | US Market | |
---|---|---|---|
7D | 20.0% | 0.9% | 0.4% |
1Y | -37.8% | 10.3% | 28.8% |
Return vs Industry: ISCO underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ISCO underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ISCO volatility | |
---|---|
ISCO Average Weekly Movement | 60.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ISCO's share price has been volatile over the past 3 months.
Volatility Over Time: ISCO's weekly volatility has increased from 43% to 60% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 30 | Andrey Semechkin | https://www.internationalstemcell.com |
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.
International Stem Cell Corporation Fundamentals Summary
ISCO fundamental statistics | |
---|---|
Market cap | US$821.65k |
Earnings (TTM) | US$195.00k |
Revenue (TTM) | US$8.33m |
4.2x
P/E Ratio0.1x
P/S RatioIs ISCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ISCO income statement (TTM) | |
---|---|
Revenue | US$8.33m |
Cost of Revenue | US$3.45m |
Gross Profit | US$4.88m |
Other Expenses | US$4.68m |
Earnings | US$195.00k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.024 |
Gross Margin | 58.54% |
Net Profit Margin | 2.34% |
Debt/Equity Ratio | 776.4% |
How did ISCO perform over the long term?
See historical performance and comparison